期刊文献+

铂类抗肿瘤药物米铂的合成及结构表征 被引量:7

Synthesis and structural characterization of miriplatin,a platinum-based anti-tumor drug
原文传递
导出
摘要 目的:合成抗肿瘤新药米铂。方法:以顺式-(1R,2R)-1,2-环己二胺-二碘合铂(环铂)、硝酸银、正十四碳酸、氢氧化钠为原料合成米铂,采用元素分析、质谱、红外光谱、核磁共振氢谱和热分析对其结构进行表征。结果:合成的化合物结构与标题化合物一致,产率约73%。结论:该方法便于操作,产率高,适合进一步研究。 Objective: To synthesize the platinum-based anti-tumor drug miriplatin. Methods: Miriplatin was prepared from (1R,2R) -1,2-cyclohexanediamine-N, N/ ) platinum (II) diiodide, silver nitrate, myristic acid and sodium hydroxide. The structure was characterized by elemental analysis, ESI-MS, FT-IR, 1H-NMR and thermal analysis. Results: The structure was consistent with the title compound, and the yield was about 73%. Conclusion : A practical synthesis procedure is developed, which has advantages of easier operation and higher yield ; it is suitable for the further studies of miriplatin.
出处 《中国新药杂志》 CAS CSCD 北大核心 2011年第17期1715-1717,共3页 Chinese Journal of New Drugs
基金 昆明市重点科技计划项目(08G100110) 五华区科技计划项目(201037)
关键词 米铂 合成 表征 热稳定性 miriplatin synthesis characterization thermal stability
  • 相关文献

参考文献9

  • 1KISHIMOTO S, NOGUCHI T, YAMAOKA T, et al. In vitro release of SM-11355, cis[ ( ( iR, 2R) -1,2-cyclohexanediamine-N, N') bis(myristato) ] platinum (II) suspended in lipiodol [ J 1. Biol Pharm Bull, 2000, 23 (5) : 637 - 640.
  • 2HANADA M, BABA A, TSUTSUMISHITA Y, et al. Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis [ J]. Cancer Chemoth Pharm, 2009, 64 (3) : 473 - 483.
  • 3FUJIYAMA S, SHIBATA J, MAEDA S, et al. Phase I clinical study of a novel lipophilic platinum complex (SM-11355) in patients with hepatocellular carcinoma refractory to cisplatin/lipiodo| [J]. BrJCancer, 2003, 89(9): 1614-1619.
  • 4KISHIMOTO S, NOGUCHI T, YAMAOKA T, et al. Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly-growing rat hepatic tumor after intra-hepatic arterial administration[J]. Biol Pharm Bull, 2000, 23(3) : 344 -348.
  • 5KISHIMOTO S, MIYAZAWA K, TERAKAWA Y, et al. Cytotoxicity of cis-[ ( ( 1R ,2R) -1,2-cyclohexanediamine-N,N') bis( myristato) l-platinum(II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line[ J ]. Jpn J Cancer Res, 2000, 91(12) : 1326 -1332.
  • 6OKUSAKA T, OKADA S, NAKANISHI T, et al. Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355 ) in patients with hepatocellular carcinoma [ J]. Invest New Drugs, 2004, 22(2) : 169 -176.
  • 7MAEDA M, SASAKI T. Liposoluble platinum (II) complex and preparation thereof: EUR, 0193936 ( B1 ) [ P ]. 1986 - 03 - 05.
  • 8TANNO N, KISHIMOTO H, NAKATSU M. Fat soluble platinum (ii) complex hydrate: JPN, 11315085 (A)[P]. 1999-11 - 16.
  • 9YOKOYAMA T; KISHIMOTO H. Method for preparing platinum complex: JPN, 2004083508 (A) [ P]. 2004 -03 - 18.

同被引文献60

引证文献7

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部